ProQR Announces Planned Changes to Board Composition

Core Viewpoint - ProQR Therapeutics is undergoing changes in its Board composition as part of its commitment to corporate governance and long-term succession planning, with two co-founders rotating off the Board at the upcoming Annual General Meeting [1][2]. Group 1: Board Changes - Dinko Valerio and Alison Lawton will step down from the Board at the next AGM as their terms conclude [1]. - An executive search firm has been engaged to identify new candidates for the Board to support long-term value creation [2]. - The Board regularly reviews its composition to ensure a balance of skills and experience, having appointed two new members in the last three years [3]. Group 2: Axiomer Technology - ProQR is pioneering a next-generation RNA base editing technology called Axiomer, which aims to create a new class of medicines for various diseases [4][5]. - Axiomer Editing Oligonucleotides (EONs) facilitate specific single nucleotide changes in RNA, potentially correcting disease-causing mutations and modulating protein expression [4]. Group 3: Company Mission - ProQR is dedicated to transforming lives through innovative RNA therapies, focusing on unmet medical needs for both rare and prevalent diseases [5].